Nadolol

Iz Wikipedije, slobodne enciklopedije
Nadolol
(IUPAC) ime
rel-(2R,3S)-5[(2R)-3-(tert-butilamino)-2-hidroksipropil]oksi1,2,3,4-tetrahidronafthalen-2,3-diol
(2R*,3S*)-5[(2R*)-3-(tert-butilamino)-2-hidroksipropil]oksi1,2,3,4-tetrahidronafthalen-2,3-diol
Klinički podaci
Robne marke Corgard
AHFS/Drugs.com Monografija
MedlinePlus a682666
Identifikatori
CAS broj 42200-33-9
ATC kod C07AA12
PubChem[1][2] 39147
DrugBank DB01203
ChemSpider[3] 35815
UNII FEN504330V YesY
KEGG[4] D00432 YesY
ChEMBL[5] CHEMBL649 YesY
Hemijski podaci
Formula C17H27NO4 
Mol. masa 309,401 g/mol
SMILES eMolekuli & PubHem
Farmakokinetički podaci
Vezivanje za proteine plazme 30%
Metabolizam Nil
Poluvreme eliminacije 14-24 sata
Izlučivanje Renalno i fekalno (nepromenjen)
Farmakoinformacioni podaci
Trudnoća C(US)
Pravni status POM (UK) -only (SAD)
Način primene Oralnot

Nadolol (Corgard, Anabet, Solgol, Corzide, Alti-Nadolol, Apo-Nadol, Novo-Nadolol) je neselektivni beta blokator koji se koristi za lečenje visokog krvnog pritiska, migrenskih glavobolja, i bola u grudima.[6][7]

Vidi još[uredi - уреди | uredi izvor]

Reference[uredi - уреди | uredi izvor]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). "Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining". J Cheminform 2 (1): 3. PMID 20331846. doi:10.1186/1758-2946-2-3.  edit
  4. Joanne Wixon, Douglas Kell (2000). "Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG". Yeast 17 (1): 48–55. doi:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H. 
  5. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). "ChEMBL: a large-scale bioactivity database for drug discovery". Nucleic Acids Res 40 (Database issue): D1100–7. PMID 21948594. doi:10.1093/nar/gkr777.  edit
  6. Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7. http://books.mcgraw-hill.com/medical/goodmanandgilman/. 
  7. Pdr Staff (2009). PDR: Physicians Desk Reference 2010 (Physicians' Desk Reference (Pdr)). Rozelle, N.S.W: Thomson Reuters. ISBN 1-56363-748-0. http://www.pdr.net/Default.aspx. 


Literatura[uredi - уреди | uredi izvor]

  • Buice RG, Subramanian VS, Duchin KL, Uko-Nne S. (1996). "Bioequivalence of a highly variable drug: an experience with nadolol". Pharmaceutical Research 13 (7): 1109–15. PMID 8842054. doi:10.1023/A:1016031313065. 
  • N. Hanania, S. Singh, R. El-Wali, et al. The safety and effects of the beta-blocker, nadolol, in mild asthma: An open-label pilot study, Pulmonary Pharmacology & Therapeutics, Volume 21, Issue 1, Pages 134-141

Spoljašnje veze[uredi - уреди | uredi izvor]


Star of life.svg Molimo Vas, obratite pažnju na važno upozorenje u vezi tema o zdravlju (medicini).